Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule (HPV-022 PRI)

The purpose of this study is to assess the occurrence of serious adverse events (SAEs) as well as evaluate the occurrence of solicited local and solicited general symptoms and the occurrence of medically significant conditions reported throughout the study period.

Study Overview

• Status: Unknown
• Conditions: Human Papillomavirus (HPV) Vaccine
• Intervention / Treatment: Biological: HPV-16/18 L1 VLP AS04 vaccine

• Study Type: Interventional
• Enrollment (Anticipated): 222
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: son hoa hoang, medicine doctor; Phone Number: 84(4)5595167; Email: hoanghoason2005@yahoo.com.vn

Study Locations

• Vietnam
  • Ha nam, Vietnam, 084
    • Recruiting
    • Thi Son commune health center and Ngoc Son Commune Health Center
    • Contact: son hoa hoang, medicine doctor; Phone Number: 84(4)5595167; Email: hoanghoason2005@yahoo.com.vn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 25 years to 40 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Subjects who the investigator believes that they can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for vaccination visits and for the follow-up visit) should be enrolled in the study.

  • The female subject should be:

• married
• of Vietnamese origin, residing in Vietnam, and

• between, and including, 25 to 40 years of age at the time of the first vaccination.

  • Written informed consent obtained from the subject (prior to enrolment).
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Subjects must have a negative urine pregnancy test.
  • Subjects of childbearing potential (i.e. active menstrual cycle) at the time of study entry:
• must not be pregnant
• and must be abstinent (and if so, this must be documented in the source documents at each vaccination visit)
• or must be using adequate contraceptive precautions (i.e. intrauterine contraceptive device, oral contraceptives, diaphragm or condom in combination with contraceptive jelly, cream or foam, progestogen-only implantable cutaneous hormonal patch or injectable contraceptives) for 30 days prior to vaccination and must agree to continue such precautions for one month after completion of the vaccination series.

Exclusion Criteria:

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period and up to one month after the last vaccine dose.

  • Subjects who have delivered recently or breastfeeding women must have completed a period of at least 3 months post-pregnancy and should not be breast-feeding in order to be enrolled in the study.

Planning to become pregnant or likely to become pregnant (as determined by the investigator) or planning to discontinue contraceptive precautions during the study period.

• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs on 14 consecutive days within six months prior to the first vaccine dose and up to one month after the last dose of the vaccine. (For corticosteroids, this will mean prednisone, or equivalent, ≥ 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
• Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before (Days - 1 to - 30) and 30 days (i.e. Days 0 - 29) after the first dose of vaccine. However, the administration of tetanus toxoid vaccine up to 8 days before the first dose of study vaccine is allowed. Enrolment will be deferred until the subject is outside of specified window.
• Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period.
• Any medically diagnosed or suspected immunodeficient condition such as human immunodeficiency virus (HIV) infection based on medical history and physical examination (no laboratory testing required).
• History of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the study vaccines, e.g. AS04, aluminium, MPL.
• Hypersensitivity to latex (found in syringe-tip cap and plunger).
• Known acute or chronic, clinically significant system conditions, e.g. neurologic,pulmonary, cardiovascular, hepatic, renal functional abnormality or psychiatric disorders, as determined by medical history, physical examination or previous laboratory tests.
• History of chronic condition(s) requiring treatment such as cancer, chronic hepatic or kidney disease(s), diabetes, or autoimmune disease. This exclusion criterion should be understood as exclusion of subjects having significant medical conditions (such as cancer, autoimmune diseases) currently under treatment.
• Acute disease at the time of enrolment. Acute disease is defined as the presence of a moderate or severe illness with or without fever. Enrolment will be deferred until condition is resolved. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. oral/ axillary temperature < 37.5 °C (99.5 °F).
• A subject with body temperature (i.e. fever) > 37.5 °C (99.5 °F).
• Drug and/or alcohol abuse.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
To assess the occurrence of serious adverse events (SAEs) throughout the study	7 months

Secondary Outcome Measures

Outcome Measure	Time Frame
To evaluate the occurrence of solicited local and solicited general symptoms and the occurrence of unsolicited symptoms as well as the occurrence of medically significant conditions.	7 months

Collaborators and Investigators

• Sponsor: National Institute for Control of Vaccine and Biologicals
• Investigators: Principal Investigator: Son Hoa Hoang, Medicine Doctor, National Institute for Control of Vaccine and Biologicals

Study record dates

Study Major Dates

• Study Start: November 1, 2007
• Study Completion (Anticipated): June 1, 2008

Study Registration Dates

• First Submitted: December 11, 2007
• First Submitted That Met QC Criteria: December 11, 2007
• First Posted (Estimate): December 12, 2007

Study Record Updates

• Last Update Posted (Estimate): December 12, 2007
• Last Update Submitted That Met QC Criteria: December 11, 2007
• Last Verified: October 1, 2007

More Information

Terms related to this study

• Other Study ID Numbers: 111040 (HPV-022 PRI)